Association of ERCC1 and BRCA1 Expression with Clinical and Pathological Features and Sensitivity to Platinum-containing Adjuvant Chemotherapy in Patients with Ovarian Epithelial Carcinoma / 医药导报

Objective To investigate the association of ERCC1 and BRCA1 gene expression with clinical features and sensitivity to platinum-containing chemotherapy in patients with ovarian epithelial carcinoma. Methods Primary ovarian epithelial carcinoma tissues were harvested from 48 patients receiving staging surgery or cytoreductive surgery. Expression of ERCC1 and BRCA1 in the tumor samples was detected by immunohistochemistry. Results ERCC1 expression was correlated with clinical stage(P﹤0. 05)but not with age,pathological type or degree of differentiation(P﹥0. 05). BRCA1 expression was not correlated with any of the clinicopathological features(P﹥0. 05);ERCC1 expression was significantly higher in drug-resistant tissues than in drug-sensitive samples(P﹤0. 05);The expression of ERCC1 and BRCA1 was positive in 89. 58%and 25. 00%of the samples,respectively. Conclusion ERCC1 gene expression is correlated with clinical stage but not with age,pathological type or degree of differentiation. BRCA1 gene expression is not correlated with clinicopathological features. ERCC1 has high positive expression in epithelial ovarian cancer and is correlated with sensitivity of platinum-containing adjuvant chemotherapy.

Effect on Cytotoxicity by Blocking ERCC1 Gene Expression in Ovarian Cancer Cell Lines / 中国肿瘤生物治疗杂志

Objective: To study the effect on cytotoxicity and drug resistance by blocking ERCCl gene expression in o-varian cancer cell lines. Methods: ERGC1 antisense expression vector was constructed and transfected into human ovarian cancer cell lines. Northern blotting and Western blotting were used to detect the RNA and protein expression level in the cells. Luciferase assay system was used to reveal the host cell reactivation function. MTT assay was used to study the effect on cytotoxicity and drug resistance in the cell lines. Results: After transfection of the antisense ERCCl, Northern and Western blotting indicated that the RNA and protein expression level of ERCCl was obviously decreased. Luciferease assay showed reduced DNA-damage repair capacity as assessed by host cell reactivation. MTT assay also showed decreased drug resistance to cisplatin in the lines. Conclusion: Transfection of antisense ERCCl may enhance the cisplatin cytotoxicity by disturbing the NER pathway in cisplatin-resistant cell lines.